Monster downgraded, Five Below upgraded: Wall Street's top analyst calls

In this article:
Monster downgraded, Five Below upgraded: Wall Street's top analyst calls
Monster downgraded, Five Below upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

  • Wells Fargo upgraded Five Below (FIVE) to Overweight from Equal Weight with an unchanged price target of $180. While the company "has had its share of issues and now seems poised to lower guidance against a choppy backdrop," the firm does not believe the story is broken and says the stock's risk/reward "looks very good for those with some patience."

  • HSBC upgraded UPS (UPS) to Buy from Hold with a price target of $170, up from $150. The company's Q1 results beat on tapering volume decline and an improving costs base, the firm tells investors in a research note.

  • KeyBanc upgraded Sherwin-Williams (SHW) to Overweight from Sector Weight with a $400 price target. The firm recommends taking advantage of the 13% pullback in shares since the recent peak in late March.

  • Goldman Sachs upgraded TJX (TJX) to Buy from Neutral with a price target of $110, up from $100. The firm views TJX as a "best-in-class operator and market share winner."

  • Needham upgraded Silicon Labs (SLAB) to Buy from Hold with a $150 price target. The firm believes the company is well positioned for the semiconductor cyclical recovery.

Top 5 Downgrades:

  • Truist downgraded Monster Beverage (MNST) to Sell from Buy with a price target of $46, down from $65. While the firm still views Monster as "a great company," it no longer sees it as a high growth story. JPMorgan also downgraded Monster Beverage to Neutral from Overweight with a price target of $59, down from $66, ahead of the company's Q1 earnings report on May 8.

  • BofA downgraded Deckers Outdoor (DECK) to Neutral from Buy with a price target of $860, down from $875, as the firm sees a better risk/reward elsewhere in its coverage.

  • Barclays downgraded Li Auto (LI) to Equal Weight from Overweight with a price target of $25, down from $39, citing competition. Industry sales data show that sales of Li's L series have been soft in recent weeks, as the company cut prices across its entire L series of SUVs and the Mega model for the first time in its history, the firm tells investors in a research note.

  • Needham downgraded HashiCorp (HCP) to Hold from Buy without a price target after the company agreed to be acquired by IBM (IBM) for $35 per share in cash. Scotiabank and Truist also downgraded HashiCorp to Neutral-equivalent ratings.

  • Wedbush downgraded First Industrial Realty (FR) to Neutral from Outperform with a price target of $49, down from $59. The firm thinks the stock and industrial real estate investment trust sector will have a hard time outperforming.

Top 5 Initiations:

  • Bernstein initiated coverage of General Motors (GM) with an Outperform rating and $55 price target. The firm expects GM's 2024 performance to push the stock higher, saying management "has four distinct opportunities to realize more value still."

  • Goldman Sachs initiated coverage of Victoria's Secret (VSCO) with a Sell rating and $14 price target. The firm sees a less attractive risk/reward relative to other companies in the brands and apparel sector over the near term.

  • Craig-Hallum initiated coverage of Ribbon Communications (RBBN) with a Buy rating and $6 price target. The firm notes Ribbon reported solid results and reiterated its outlook for the remainder of 2024.

  • Wells Fargo initiated coverage of Americold Realty Trust (COLD) with an Equal Weight rating and $24 price target. While the Cold Storage industry is poised for growth, the firm expects occupancy moderation and throughput weakness at Americold Realty Trust near term, as consumers face continued inflationary and rate-driven headwinds.

  • H.C. Wainwright initiated coverage of Processa Pharmaceuticals (PCSA) with a Buy rating and $8 price target. The company is optimizing existing chemotherapeutic agents to enhance safety, tolerability and effectiveness for a wide array of cancer sufferers, the firm tells investors in a research note.

Advertisement